Trial Profile
Mobilsation kinetics following late afternoon dosing with plerixafor in patients with multiple myeloma or non-Hodgkin's lymphoma undergoing stem-cell mobilisation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2014
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Multiple myeloma; Non-Hodgkin's lymphoma; Stem cell mobilisation
- Focus Pharmacodynamics
- 13 Oct 2014 New trial record